Siemens Healthineers AG banner

Siemens Healthineers AG
F:SHL1

Watchlist Manager
Siemens Healthineers AG Logo
Siemens Healthineers AG
F:SHL1
Watchlist
Price: 16.6 EUR -0.6% Market Closed
Market Cap: €37.1B

Wall St Price Targets

SHL1 Price Targets Summary
Siemens Healthineers AG

Wall Street analysts forecast SHL1 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SHL1 is 25.55 EUR with a low forecast of 19.09 EUR and a high forecast of 32.19 EUR.

Lowest Forecast
Price Target
19.09 EUR
15% Upside
Average Forecast
Price Target
25.55 EUR
54% Upside
Highest Forecast
Price Target
32.19 EUR
94% Upside
Siemens Healthineers AG Competitors:
Price Targets
FOXA
Fox Corp
28% Upside
ZIP
Ziprecruiter Inc
-3% Downside
PMT
PennyMac Mortgage Investment Trust
14% Upside

Revenue
Forecast

6% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 5%.

Gross Profit
Forecast

6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 6%.

Operating Income
Forecast

5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 15%.

Pre-Tax Income
Forecast

5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
5% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 15%.

Net Income
Forecast

6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
6% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 9 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 16%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SHL1's stock price target?
Price Target
25.55 EUR

According to Wall Street analysts, the average 1-year price target for SHL1 is 25.55 EUR with a low forecast of 19.09 EUR and a high forecast of 32.19 EUR.

What is the Revenue forecast for Siemens Healthineers AG?
Projected CAGR
5%

Over the last 9 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 5%.

What is the Gross Profit forecast for Siemens Healthineers AG?
Projected CAGR
6%

Over the last 9 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 6%.

What is the Operating Income forecast for Siemens Healthineers AG?
Projected CAGR
15%

Over the last 9 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 15%.

What is the Pre-Tax Income forecast for Siemens Healthineers AG?
Projected CAGR
15%

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 15%.

What is the Net Income forecast for Siemens Healthineers AG?
Projected CAGR
16%

Over the last 9 years, the compound annual growth rate for Net Income has been 6%. The projected CAGR for the next 3 years is 16%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett